RU2012151500A - Композиции и способы, пригодные для снижения вязкости белковосодержащих составов - Google Patents
Композиции и способы, пригодные для снижения вязкости белковосодержащих составов Download PDFInfo
- Publication number
- RU2012151500A RU2012151500A RU2012151500/15A RU2012151500A RU2012151500A RU 2012151500 A RU2012151500 A RU 2012151500A RU 2012151500/15 A RU2012151500/15 A RU 2012151500/15A RU 2012151500 A RU2012151500 A RU 2012151500A RU 2012151500 A RU2012151500 A RU 2012151500A
- Authority
- RU
- Russia
- Prior art keywords
- arginine
- composition
- protein
- viscosity
- methyl ester
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 46
- 238000000034 method Methods 0.000 title claims 23
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 235000018102 proteins Nutrition 0.000 claims abstract 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract 22
- 239000000126 substance Substances 0.000 claims abstract 20
- -1 methyl nitroarginine ester Chemical class 0.000 claims abstract 12
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract 12
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract 12
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims abstract 11
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract 11
- 239000004475 Arginine Substances 0.000 claims abstract 10
- 229960003121 arginine Drugs 0.000 claims abstract 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 9
- 235000004279 alanine Nutrition 0.000 claims abstract 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract 8
- 150000004702 methyl esters Chemical class 0.000 claims abstract 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract 7
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims abstract 6
- AKGWUHIOEVNNPC-LURJTMIESA-N Arg-OEt Chemical compound CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 claims abstract 6
- BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 claims abstract 6
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims abstract 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract 6
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 claims abstract 6
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims abstract 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000004472 Lysine Substances 0.000 claims abstract 6
- 239000005700 Putrescine Substances 0.000 claims abstract 6
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims abstract 6
- 229960003589 arginine hydrochloride Drugs 0.000 claims abstract 6
- 229940063673 spermidine Drugs 0.000 claims abstract 6
- 229940063675 spermine Drugs 0.000 claims abstract 6
- ZDLDXNCMJBOYJV-YFKPBYRVSA-N L-arginine, methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N ZDLDXNCMJBOYJV-YFKPBYRVSA-N 0.000 claims abstract 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract 5
- XNBJHKABANTVCP-UHFFFAOYSA-N 2-amino-3-(diaminomethylideneamino)propanoic acid Chemical compound OC(=O)C(N)CN=C(N)N XNBJHKABANTVCP-UHFFFAOYSA-N 0.000 claims abstract 4
- 108010016626 Dipeptides Proteins 0.000 claims abstract 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims abstract 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 4
- 239000004202 carbamide Substances 0.000 claims abstract 4
- 229960002173 citrulline Drugs 0.000 claims abstract 4
- 235000013477 citrulline Nutrition 0.000 claims abstract 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960001340 histamine Drugs 0.000 claims abstract 4
- 229960004452 methionine Drugs 0.000 claims abstract 4
- 229930182817 methionine Natural products 0.000 claims abstract 4
- 229960003104 ornithine Drugs 0.000 claims abstract 4
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims abstract 4
- 108010011110 polyarginine Proteins 0.000 claims abstract 4
- CYUKTRXBNIAEBL-YFKPBYRVSA-N methyl (2s)-5-(diaminomethylideneamino)-2-nitramidopentanoate Chemical compound COC(=O)[C@@H](N[N+]([O-])=O)CCCNC(N)=N CYUKTRXBNIAEBL-YFKPBYRVSA-N 0.000 claims abstract 2
- 235000018977 lysine Nutrition 0.000 claims 6
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 claims 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 claims 1
- HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 abstract 1
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33068910P | 2010-05-03 | 2010-05-03 | |
| US61/330,689 | 2010-05-03 | ||
| PCT/US2011/034001 WO2011139718A1 (en) | 2010-05-03 | 2011-04-26 | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012151500A true RU2012151500A (ru) | 2014-06-10 |
Family
ID=44263176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012151500/15A RU2012151500A (ru) | 2010-05-03 | 2011-04-26 | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130058958A1 (enExample) |
| EP (1) | EP2566510A1 (enExample) |
| JP (1) | JP2013525484A (enExample) |
| KR (1) | KR20130060227A (enExample) |
| CN (1) | CN102958538A (enExample) |
| BR (1) | BR112012027828A2 (enExample) |
| CA (1) | CA2794864A1 (enExample) |
| MX (1) | MX2012012743A (enExample) |
| RU (1) | RU2012151500A (enExample) |
| WO (1) | WO2011139718A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694708A4 (en) * | 2011-04-07 | 2014-10-01 | Glaxosmithkline Llc | FORMULATIONS WITH REDUCED VISCOSITY |
| US9574005B2 (en) | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
| CN108704132A (zh) | 2011-10-31 | 2018-10-26 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| US9169304B2 (en) * | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| JP6157611B2 (ja) * | 2012-06-21 | 2017-07-05 | ユセベ ファルマ ソシエテ アノニム | 医薬製剤 |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| FR2995214B1 (fr) | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JP6179939B2 (ja) * | 2013-07-09 | 2017-08-16 | 国立大学法人 筑波大学 | 高濃度γグロブリン製剤の粘度低下方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| CN104740630A (zh) * | 2013-12-25 | 2015-07-01 | 浙江海正药业股份有限公司 | 一种含有抗cd52单抗的药物组合物 |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| WO2016054259A1 (en) | 2014-10-01 | 2016-04-07 | Arsia Therapeutics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| JP2017531682A (ja) | 2014-10-23 | 2017-10-26 | アムジエン・インコーポレーテツド | 医薬製剤の粘度低下 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MA41629A (fr) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2017095848A1 (en) * | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| AU2018258676B2 (en) * | 2017-04-28 | 2024-09-19 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| EP3615065A1 (en) | 2017-04-28 | 2020-03-04 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| US11590237B2 (en) * | 2017-05-18 | 2023-02-28 | Merck Sharp & Dohme Llc | Pharmaceutical formulation comprising incretin-insulin conjugates |
| BR112020004325A2 (pt) | 2017-09-05 | 2020-10-06 | Merck Sharp & Dohme Corp. | compostos para reduzir a viscosidade de formulações biológicas |
| BR112020021094A2 (pt) * | 2018-04-16 | 2021-02-23 | Merck Patent Gmbh | redução da viscosidade de formulações de proteínas altamente concentradas |
| PT4364724T (pt) | 2018-05-10 | 2025-12-16 | Regeneron Pharma | Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| GB201900728D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Birmingham | Drug delivery system |
| JP7791813B2 (ja) * | 2019-09-17 | 2025-12-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 高濃縮タンパク質製剤中の粘度低減剤としてのカンファースルホン酸およびそのカチオン性賦形剤との組み合わせ |
| AU2020402994A1 (en) | 2019-12-11 | 2022-06-23 | Inspirna, Inc. | Methods of treating cancer |
| PL4045533T3 (pl) | 2020-03-26 | 2024-04-15 | Vanderbilt University | Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2) |
| JP2023533704A (ja) * | 2020-07-13 | 2023-08-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ |
| EP4319795A4 (en) * | 2021-04-09 | 2025-03-05 | Avantor Performance Materials, LLC | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
| US20250325475A1 (en) * | 2021-10-29 | 2025-10-23 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| WO2023075702A1 (en) * | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| TW202342095A (zh) * | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防ｃｏｖｉｄ—１９之組成物 |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5078998A (en) | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| ATE113846T1 (de) | 1988-06-21 | 1994-11-15 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| ES2296839T3 (es) | 1991-08-14 | 2008-05-01 | Genentech Inc. | Variantes de inmunoglobulinas para receptores fc-epsilon especificos. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1995016203A2 (en) | 1993-12-10 | 1995-06-15 | Genentech, Inc. | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
| AP660A (en) | 1994-01-18 | 1998-08-18 | Genentech Inc | A method of treatment of parasitic infection using IgE antagonists. |
| CA2181787A1 (en) | 1994-03-03 | 1995-09-08 | Claire M. Doerschuk | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
| AU695323B2 (en) | 1994-09-09 | 1998-08-13 | Takeda Chemical Industries Ltd. | Sustained release preparation containing metal salt of a peptide |
| EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| WO1996040072A2 (en) | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| AU724449B2 (en) | 1996-01-23 | 2000-09-21 | Genentech Inc. | Anti-CD18 antibodies for use against stroke |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| DK1516629T3 (da) | 1996-11-27 | 2013-06-03 | Genentech Inc | Humaniseret anti-CD-11a antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| ES2293682T5 (es) | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| ES2329437T3 (es) | 1999-06-25 | 2009-11-26 | Genentech, Inc. | Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2. |
| CN1413220A (zh) | 1999-10-29 | 2003-04-23 | 杰南技术公司 | 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法 |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| ATE442862T2 (de) * | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| WO2003033658A2 (en) | 2001-10-17 | 2003-04-24 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| ES2351786T3 (es) * | 2001-11-13 | 2011-02-10 | Genentech, Inc. | Formulaciones con ligando apo2/trail y usos de las mismas. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003208415B2 (en) | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| EA021644B1 (ru) | 2002-10-17 | 2015-08-31 | Генмаб А/С | Человеческое моноклональное антитело против cd20 и его применение |
| PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
| RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| US20070212346A1 (en) * | 2003-10-09 | 2007-09-13 | Tomoyuki Igawa | Highly Concentrated Stabilized Igm Solution |
| NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2007076062A2 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2011
- 2011-04-26 JP JP2013509113A patent/JP2013525484A/ja active Pending
- 2011-04-26 KR KR20127031426A patent/KR20130060227A/ko not_active Withdrawn
- 2011-04-26 CA CA 2794864 patent/CA2794864A1/en active Pending
- 2011-04-26 EP EP20110720633 patent/EP2566510A1/en not_active Withdrawn
- 2011-04-26 BR BR112012027828A patent/BR112012027828A2/pt not_active IP Right Cessation
- 2011-04-26 CN CN2011800320023A patent/CN102958538A/zh active Pending
- 2011-04-26 MX MX2012012743A patent/MX2012012743A/es not_active Application Discontinuation
- 2011-04-26 WO PCT/US2011/034001 patent/WO2011139718A1/en not_active Ceased
- 2011-04-26 RU RU2012151500/15A patent/RU2012151500A/ru not_active Application Discontinuation
-
2012
- 2012-11-02 US US13/666,990 patent/US20130058958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130060227A (ko) | 2013-06-07 |
| BR112012027828A2 (pt) | 2016-08-09 |
| WO2011139718A1 (en) | 2011-11-10 |
| CN102958538A (zh) | 2013-03-06 |
| JP2013525484A (ja) | 2013-06-20 |
| US20130058958A1 (en) | 2013-03-07 |
| MX2012012743A (es) | 2012-11-23 |
| EP2566510A1 (en) | 2013-03-13 |
| CA2794864A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012151500A (ru) | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов | |
| JP2013525484A5 (enExample) | ||
| JP2017533218A5 (enExample) | ||
| JP2013524817A5 (enExample) | ||
| RU2012144626A (ru) | Композиции и способы, используемые для стабилизации белоксодержащих готовых форм | |
| EA200970880A1 (ru) | Стабильные композиции на основе антител | |
| HRP20200101T1 (hr) | Glikopeptidni pripravci | |
| RU2008137634A (ru) | Способ уменьшения агрегации белка | |
| RU2012144316A (ru) | Стабильные составы бортезомиба | |
| CN103472235A (zh) | 一种长效蛋白质溶液稳定剂 | |
| AU2018231364B2 (en) | Culture medium comprising oligopeptides | |
| RU2012118386A (ru) | Стабилизирующий эксципиент для вакцины с инактивированными целыми вирусами | |
| ATE437647T1 (de) | Transporter mit beabstandeten arginin-teilchen | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| CN103472222B (zh) | 一种长效酶标板稳定剂 | |
| RU2015154214A (ru) | Стабильные композиции иммуноглобулинового одиночного вариабельного домена и их применение | |
| JP2014527072A5 (enExample) | ||
| CA2916222A1 (en) | Stable liquid formulation of amg 416 (etelcalcetide) | |
| RU2009137380A (ru) | Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения | |
| JP5774561B2 (ja) | 安定なボルテゾミブ製剤 | |
| RU2019130728A (ru) | Жидкая композиция антитела против TNF альфа | |
| CN102670522A (zh) | 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备 | |
| JP2013542954A5 (enExample) | ||
| CN105777858B (zh) | 多种抗体的复合稳定剂及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150710 |